Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide.
Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by adwaitcoherent and here's what we found interesting.
Average Info
Notes Per Post
0
Likes Per Post
0
Reblog Per Post
0
Reply Per Post
0
Time Between Posts
10 hours
Number of Posts By Type
Text
2
Link
15
Last Seen Tumblr Blogs
Fun Fact
70% of Tumblr users say the Dashboard is their favorite place to spend time online.
Text
By 2026, Intracranial Stents Market To Surpass US$ 1,143.0 Million - Coherent Market Insights
Intracranial Stents Market To exhibit a CAGR of 15.6% over the forecast period (2018 - 2026).
Request for Sample PDF Copy:
https://www.coherentmarketinsights.com/insight/request-pdf/1870
Description:
Narrowing of the blood vessels or blood clots due to building up of fats, plaque, and other substances in the blood vessels is called intracranial stenosis. This condition marks with a stroke either to the carotid artery in the neck or in an intracranial artery. Stents during this condition act as a permanent implant which allows blood flow to the brain by opening the blocked arteries. Angioplasty (use of balloon catheter) along with placement of a stent may be an appropriate treatment for the patients who have had a stroke or transient ischemic attack (TIA). However, since these stents are designed for use in the heart, it is complex to use them in the arteries of the brain. Though, with the advent of the new self-expanding brain stents, the rate of reoccurrence of artery narrowing can be lowered. For instance, Acclino microstent offered by Acandis GmbH, shows a satisfactory safety profile and a promising rate of immediate and mid-term complete aneurysm occlusion for stent-assisted coil embolization in wide-neck intracranial aneurysms.
The global intracranial stents market size was valued at US$ 313.5 million in 2017, and is expected to witness a CAGR of 15.6% over the forecast period (2018 – 2026).
Figure 1. Global Intracranial Stents Market Share Analysis (%), By Region, 2017
Intracranial Stents | Coherent Market Insights
Source: Coherent Market Insights Analysis (2018)
Intracranial Stents Market Dynamics
Increasing incidence of stroke and brain aneurysm is propelling demand for intracranial stents. According to the Brain Aneurysm Foundation (BAF), brain aneurysm accounts for around 500,000 deaths worldwide annually. Moreover, BAF estimates that aneurysm is predominant in the age group of 35–60 years. Furthermore, high prevalence of stroke among geriatric population worldwide is also expected to propel demand for intracranial stents in the near future. According to the data published in the Medscape, 2010, around 75-89% of strokes occur in individuals aged > 65 years. Of these strokes, 50% occur in people who are aged ≥ 70 years and nearly 25% occur in individuals who are aged > 85 years.
Integration of advanced software with existing products are gaining significant traction among various market players of intracranial stents with affordable costs thus, expected to drive intracranial stents market growth. For instance, in September 2016, Medtronic plc received the U.S. Food and Drug Administration (FDA) approval for its StealthStation, which is integrated with Medtronic’s latest O-arm Imaging System, enabling clinicians to place the deep brain stimulation (DBS) leads with high level of accuracy during the cranial procedures.
However, high cost of the procedure and limited use of various intracranial stents to a small population may impact the overall market to some extent. For instance, in August 2012, the U.S. FDA approved label changes for the Wingspan Stent System offered by Stryker Corporation, reflecting changes in indications for use, and limiting the system to a much smaller group of patients between 22 and 80 years with intracranial stenosis.
Intracranial Stents Market Regional Outlook
On the basis of geography, the global intracranial stents market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to hold dominant position in this market, owing to increasing geriatric population who are more prone to brain diseases and adoption of technologically advanced products such as adoption of cranio maxillofacial implants. Emerging economies are also projected to witness significant growth in market over the forecast period, owing to high prevalence of intracranial strokes. For instance, according to the American Journal of Neuroradiology, 2011, intracranial cerebral atherosclerosis disease (ICAD) accounts for around 8%–10% of all ischemic strokes with a higher reported incidence in the Asian, African, and Hispanic descent populations. The factors responsible for disease prevalence in these regions includes cigarette smoking, hypertension, insulin-dependent diabetes mellitus, and hypercholesterolemia. Thus, emerging economies such as Asia Pacific and Latin America is likely to be the fastest growing region throughout the forecast period.
Major companies operating in the global intracranial stents market include Medtronic Plc, Balt Extrusion S.A., MicroPort Scientific Corporation, Abbott Laboratories, Stryker Corporation, Admedes Schuessler GmbH, Cardiatis, S.A, DePuy Synthes, Acandis GmbH, and Penumbra, Inc.
About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.
Buy Report Here:
https://www.coherentmarketinsights.com/insight/buy-now/1870
Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
0 notes
Text
By 2026, Avascular Necrosis Market To Surpass US$ 840 Million - Coherent Market Insights
Avascular Necrosis Market To exhibit a CAGR of 6.0% over the forecast period (2018 - 2026).
Request for Sample PDF Copy:
https://www.coherentmarketinsights.com/insight/request-pdf/2218
Description:
Avascular necrosis (AVN) also termed as osteonecrosis, or aseptic necrosis, or ischemic bone necrosis, a condition resulting in the death of bone cells due to loss of blood supply. It often leads to collapse of the joint surface and subsequent arthritis due to an irregular joint surface. Avascular necrosis affects the ends (epiphysis) of long bones such as femur, upper humerus, and bones of ankle joint. Usually it develops due to combination of various factors including metabolic, genetic, increased alcohol consumption, smoking, and other diseases.
An X-ray is generally used to diagnose cause of joint pain. However, magnetic resonance imaging (MRI), is the most sensitive method for diagnosing avascular necrosis in early stages. Unlike X-rays, bone scans, and computed/computerized tomography (CT) scans, MRI detects chemical changes in bone marrow and shows avascular necrosis in its earliest stages.
Nonsurgical treatment options for avascular necrosis such as anti-inflammatory medications, activity changes, and crutches can help relieve pain and slow progression of the disease. Surgical treatment include core decompression, bone and cartilage grafting, and total hip replacement. Based on the cause, avascular necrosis can be classified as traumatic and non-traumatic avascular necrosis.
According to the Science Direct Journal 2010 report, traumatic injury such as ankle sprain, fracture and joint dislocation is the most common cause of AVN, which can occur eight hours after disruption to the blood supply. Non-traumatic avascular necrosis occurs usually at young age and its causes include chronic liver disease, corticosteroids, decompression sickness, fat embolism syndrome, Gaucher disease, gout, hyperlipidaemia, haemoglobinopathy, metabolic bone disease, systemic chemotherapy systemic lupus erythematosus, and alcoholism among others.
The global avascular necrosis market size was valued at US$ 512.9 million in 2017, and is expected to witness a CAGR of 6.0% over the forecast period (2018 – 2026).
Global Avascular Necrosis Market Value (US$ Mn) & Y-o-Y Growth (%)
Avascular Necrosis | Coherent Market Insights
Source: Coherent Market Insights Analysis (2018)
Increasing Alcohol Consumption and Use of Corticosteroids are Expected to Drive Growth of the Avascular Necrosis Market
Excessive alcohol consumption and long-term, high dose systemic corticosteroid use are the major risk factors for avascular necrosis. According to World Journal of Orthopedics, 2015, avascular necrosis usually affects people between 30 and 50 years of age. Also, from the same source, about 10,000 to 20,000 people develop osteonecrosis each year in the U.S. According to National Organization for Rare Disorders’ 2015 data, alcohol consumption and corticosteroid use affects about 30% and 35% of all people with non-traumatic avascular necrosis, respectively across the globe.
Other risk factors or conditions associated with non-traumatic osteonecrosis include autoimmune disease, cancer, decompression disease (Caisson disease), Gaucher disease, pancreatitis, HIV infection, and blood disorders such as sickle cell disease. Certain medical treatments including radiation therapy and chemotherapy can also cause osteonecrosis. Moreover, people who have undergone organ transplants are at high developmental risk of osteonecrosis.
Technological advancement in therapies for avascular necrosis such as Advanced Therapy Medicinal Products (ATMPs) is expected to boost avascular necrosis market. Advanced Therapy Medicinal Products is a class of innovative therapies that comprises of gene therapy, somatic cell therapy, and tissue-engineered products.
Avascular Necrosis Market Restraints
High cost of surgical treatments and delay in diagnosis due to asymptomatic nature of this condition at early stage are the major restraining factors for avascular necrosis market growth. For instance, according to Blue Cross Blue Shield of North Carolina, a total hip replacement procedure usually cost between US$ 31,839 and US$ 44,816, with an average cost of US$ 39,299.
Avascular Necrosis Market - Regional Insights
On the basis of region, the global avascular necrosis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to generate a significant revenue share in global avascular necrosis market during the forecast period due to increasing prevalence of avascular necrosis and prior Food and Drug Administration (FDA) approval for the new avascular necrosis treatments in the region. For instance, according to National Center for Biotechnology Information (NCBI), 2015, about 20,000 to 30,000 new patients are diagnosed with avascular necrosis every year in the U.S.
Asia Pacific avascular necrosis market is expected to foresee highest growth rate during the forecast period, owing to increase in development activities for the treatment of avascular necrosis by various key players in this region. For instance, in 2017, Asahi Kasei Corporation and Bone Therapeutics signed a license agreement for the development and commercialization of PREOB in Japan. PREOB is an autologous osteoblastic cell therapy product derived from ex vivo cultured bone marrow cells of the patients.
Global Avascular Necrosis Market Share 2017 (%), By Region
Avascular Necrosis | Coherent Market Insights
Source: Coherent Market Insights Analysis (2018)
Avascular Necrosis Market - Competitive Landscape
Key players operating in the global avascular necrosis market include Bone Therapeutics, Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon Inc., Eli Lilly and Company, Grifols SA, Integra LifeSciences Corporation, K-Stemcell Co Ltd., Medtronic Plc, Merck KGaA, Pfizer Inc., Sanofi SA, Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings. Manufacturers are focusing on advancements in treatment technologies such as gene therapy and stem cell-based treatment for avascular necrosis.
About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.
Buy Report Here:
https://www.coherentmarketinsights.com/insight/buy-now/2218
Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
0 notes